Adicet Bio, Inc.
ACETHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Adicet Bio, Inc. (ACET) is listed under Biotechnology. The company carries a $75.9M market cap, placing it firmly in the micro-cap category. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases.
Market Cap
$75.9M
Beta
1.59
P/E (TTM)
—
P/E (Fwd)
-1.94
EPS (TTM)
$-14.18
EPS (Fwd)
$-4.19
ROE
-72.2%
ROA
-39.4%
Cash
$137.6M
Total Debt
$13.9M
Free CF
-$50.4M
52W Change
-32.5%
Annual Financials
Cash vs Debt
Where ACET stands vs its 150-day and 200-day moving averages
As of the July 10, 2026 close, ACET finished 14.62% above its 150-day moving average ($7.80) and 0.67% below its 200-day moving average ($9.00). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ACET overbought or oversold?
At the July 10, 2026 close, ACET's RSI(14) was 62.7, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $137.6M in cash comfortably exceeding the $13.9M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$50.4M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -72.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $9.7M (2021) to $0 (2025), a 100% decline worth watching.
With a beta above 1.5, ACET tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. With cash comfortably exceeding debt, ACET has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing ACET.